[R01] Targeting Regulatory T cells for Factor VIII Tolerance
Ente: National Heart Lung and Blood Institute
Scadenza: 2030-06-30
Importo max: 758.254 EUR
Paese: US
Descrizione
PROJECT SUMMARY
Children and adults with the inherited bleeding disorder hemophilia A are reliant on infusions of coagulation
protein factor VIII (FVIII) to treat bleeding episodes. The most significant complication of FVIII replacement
therapy is the formation of neutralizing antibodies called inhibitors against the infused FVIII protein. Inhibitors
increases the risk of bleeding episodes that are difficult to control, which ultimately affects quality of life. However,
the advent of novel non-factor therapies used to prevent bleeding has dramatically changed the treatment
paradigm for persons with hemophilia A (PwHA) and inhibitors. Despite the tremendous advancements in
treatment options for PwHA, none of the current therapies prevent the development of inhibitors. Moreover,
PwHA and inhibitors are still dependent on bypassing agents with reduced hemostatic efficacy than FVIII for
bleeding and surgical management. Although there have been extensive studies into understanding the adaptive
immune response to FVIII, the mechanism(s) that drive inhibitor formation are still poorly understood. It is known
that CD4+ T cells are responsible for activating B cells and plasma cells that produce FVIII antibodies. It is also
established that regulatory T cells (Tregs) are an important element of central and peripheral tolerance to
antigens, including FVIII tolerance achieved with successful immune tolerance induction therapy. It is postulated
that FVIII inhibitor formation results from an imbalance or failure in Treg-mediated immune regulatory processes.
Whether Tregs are reduced, dysfunction, or incapable of expanding in FVIII adaptive immunity warrants further
investigation. The long-term goal of this work is to illuminate key mechanisms of FVIII immune responses to
develop targeted and low burden therapies for inhibitor prevention during early FVIII exposure. We hypothesize
that FVIII inhibitor development is associated with reduced and dysfunctional Tregs, which is prevented with
Treg expansion in vivo. To test our hypothesis, we will use a combination of mouse and human model systems
to understand the Treg profile in FVIII deficiency and inhibitor development. In Aim 1, we will perform rigorous
Treg phenotyping in mouse models of hemophilia A with different in inhibitor responses and Tregs isolated from
pediatric and adult PwHA based on inhibitor status. We will additionally generate a human-derived spleen
organoid model to study the effect of FVIII on Treg responses at the primary site of FVIII interface with immune
cells. In Aim 2, we will determine the effect of engaging the erythropoietin (EPO) receptor with recombinant EPO,
a known Treg inducer in models of autoimmunity and solid-organ transplantation, on inhibitor responses in naive
hemophilia A mice. In Aim 3, we will evaluate EPO-mediated Treg expansion capacity based on age using
isolated Tregs from children with chronic kidney disease initiating EPO therapy and EPO-stimulated Tregs in
vitro
Istituzione: STANFORD UNIVERSITY
PI: Glaivy Batsuli
Progetto: 5R01HL180328-02
Settori: National Heart Lung and Blood Institute
Vai al bando originale
Registrati gratis su Bandolo per trovare bandi compatibili con la tua azienda.